NOTE: A total of 278 participants included in analysis after removing exclusion criteria.
Descriptives
Patient demographics
Overall
Characteristic
Non-conventional (n=137)
Conventional (n=141)
Total (n=278)
P-value
Age (y)at the time of result: Mean (SD)
68.81 (14.64)
65.40 (15.10)
67.08 (14.95)
0.06
Age (y)at the time of result: N(%)
0.36
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<65 years
50 (36.5)
60 (42.6)
110 (39.57)
≥65 years
87 (63.5)
81 (57.4)
168 (60.43)
Gender: N(%)
0.58
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Male
82 (59.9)
90 (63.8)
172 (61.87)
Female
55 (40.1)
51 (36.2)
106 (38.13)
Inpatient length of stay: Median (IQ range)
14.00 (8.00-25.00)
12.00 (6.00-24.00)
13.00 (7.00-24.75)
0.18
Height (cm): Mean (SD)
170.45 (10.39)
171.19 (10.34)
170.83 (10.35)
0.55
Weight (kg)within the week prior to dose: Mean (SD)
98.32 (41.03)
88.02 (26.93)
93.10 (34.92)
0.01
BMI: Median (IQ range)
29.45 (24.97-39.68)
28.93 (24.23-33.71)
29.10 (24.43-35.06)
0.13
BMI: N(%)
0.92
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<30 kg/m2
73 (53.3)
77 (54.6)
150 (53.96)
≥30 kg/m2
64 (46.7)
64 (45.4)
128 (46.04)
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: Mean (SD)
48.33 (23.15)
50.35 (27.86)
49.25 (25.36)
0.60
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: N(%)
0.002
Missing
39 (28.5)
58 (41.1)
97 (34.89)
Stage 1: >=90 ml/min
2 (1.5)
0 (0.0)
2 (0.72)
Stage 2: 60-89 ml/min
26 (19.0)
37 (26.2)
63 (22.66)
Stage 3: 30-59 ml/min
49 (35.8)
21 (14.9)
70 (25.18)
Stag3 4/5: <30 ml/min
21 (15.3)
25 (17.7)
46 (16.55)
modified CG (mL/min): Mean (SD)
55.33 (33.27)
65.27 (36.25)
60.37 (35.11)
0.02
CrCl (mL/min): N(%)
0.003
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<50 ml/min
76 (55.5)
52 (36.9)
128 (46.04)
≥50 ml/min
61 (44.5)
89 (63.1)
150 (53.96)
LMWH level: Mean (SD)
0.79 (0.32)
0.88 (0.35)
0.84 (0.34)
0.02
LMWH >1.0: N(%)
0.02
Missing
0 (0.0)
0 (0.0)
0 (0.00)
≤1.0
111 (81.0)
96 (68.1)
207 (74.46)
>1.0
26 (19.0)
45 (31.9)
71 (25.54)
LMWH
0.09
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<0.5
23 (16.8)
13 (9.2)
36 (12.95)
≥0.5
114 (83.2)
128 (90.8)
242 (87.05)
Enoxaparin dose used (mg): Mean (SD)
77.55 (32.75)
88.19 (25.46)
82.95 (29.71)
0.003
Enoxaparin dose (mg/kg): Mean (SD)
0.83 (0.30)
1.01 (0.12)
0.92 (0.24)
<0.0001
Concurrent antiplatelet or anticoagulation treatment: N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
No
136 (99.3)
140 (99.3)
276 (99.28)
Yes
1 (0.7)
1 (0.7)
2 (0.72)
Clinical events after anticoagulation (choice=Death): N(%)
0.88
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
127 (92.7)
129 (91.5)
256 (92.09)
Checked
10 (7.3)
12 (8.5)
22 (7.91)
Clinical events after anticoagulation (choice=ACS): N(%)
0.49
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
136 (99.3)
141 (100.0)
277 (99.64)
Checked
1 (0.7)
0 (0.0)
1 (0.36)
Clinical events after anticoagulation (choice=VTE): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
135 (98.5)
139 (98.6)
274 (98.56)
Checked
2 (1.5)
2 (1.4)
4 (1.44)
Clinical events after anticoagulation (choice=Ischaemic stroke in hospital): N(%)
0.24
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
135 (98.5)
141 (100.0)
276 (99.28)
Checked
2 (1.5)
0 (0.0)
2 (0.72)
Major bleeding in hospital: N(%)
0.53
Missing
1 (0.7)
1 (0.7)
2 (0.72)
Yes
8 (5.8)
5 (3.5)
13 (4.68)
No
128 (93.4)
135 (95.7)
263 (94.60)
Indication for enoxaparin(choose as many as apply) (choice=Pulmonary embolism): N(%)
0.24
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
65 (47.4)
56 (39.7)
121 (43.53)
Checked
72 (52.6)
85 (60.3)
157 (56.47)
Indication for enoxaparin(choose as many as apply) (choice=Deep vein thrombosis): N(%)
0.07
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
85 (62.0)
71 (50.4)
156 (56.12)
Checked
52 (38.0)
70 (49.6)
122 (43.88)
Indication for enoxaparin(choose as many as apply) (choice=Atrial fibrillation): N(%)
0.38
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
107 (78.1)
117 (83.0)
224 (80.58)
Checked
30 (21.9)
24 (17.0)
54 (19.42)
Indication for enoxaparin(choose as many as apply) (choice=Myocardial infarction): N(%)
0.62
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
135 (98.5)
140 (99.3)
275 (98.92)
Checked
2 (1.5)
1 (0.7)
3 (1.08)
Indication for enoxaparin(choose as many as apply) (choice=Metallic heart valve): N(%)
0.73
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
130 (94.9)
136 (96.5)
266 (95.68)
Checked
7 (5.1)
5 (3.5)
12 (4.32)
Indication for enoxaparin (Other): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Yes
137 (100.0)
140 (99.3)
277 (99.64)
Other/Unknown
0 (0.0)
1 (0.7)
1 (0.36)
Once daily dosing group: N(%)
0.03
Missing
112 (81.8)
122 (86.5)
234 (84.17)
CrCl>30 once daily enoxaparin dose <1.5mg/kg
16 (11.7)
5 (3.5)
21 (7.55)
CrCl<30 once daily enoxaparin dose <1.0mg/kg
9 (6.6)
14 (9.9)
23 (8.27)
Twice daily dosing
Characteristic
Non-conventional (n=108)
Conventional (n=112)
Total (n=220)
P-value
Age (y)at the time of result: Mean (SD)
68.22 (15.21)
64.54 (14.43)
66.35 (14.90)
0.07
Age (y)at the time of result: N(%)
0.25
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<65 years
40 (37.0)
51 (45.5)
91 (41.36)
≥65 years
68 (63.0)
61 (54.5)
129 (58.64)
Gender: N(%)
0.63
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Male
67 (62.0)
74 (66.1)
141 (64.09)
Female
41 (38.0)
38 (33.9)
79 (35.91)
Inpatient length of stay: Median (IQ range)
15.00 (8.00-24.25)
11.00 (6.00-22.00)
13.00 (7.00-22.25)
0.08
Height (cm): Mean (SD)
170.70 (10.50)
172.06 (10.01)
171.39 (10.25)
0.33
Weight (kg)within the week prior to dose: Mean (SD)
100.03 (42.22)
90.30 (28.35)
95.08 (36.09)
0.05
BMI: Median (IQ range)
29.80 (24.99-39.83)
28.96 (24.40-34.01)
29.29 (24.69-36.09)
0.17
BMI: N(%)
0.80
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<30 kg/m2
56 (51.9)
61 (54.5)
117 (53.18)
≥30 kg/m2
52 (48.1)
51 (45.5)
103 (46.82)
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: Mean (SD)
52.04 (22.31)
63.71 (19.92)
57.03 (22.02)
0.002
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: N(%)
0.001
Missing
33 (30.6)
56 (50.0)
89 (40.45)
Stage 1: >=90 ml/min
2 (1.9)
0 (0.0)
2 (0.91)
Stage 2: 60-89 ml/min
23 (21.3)
34 (30.4)
57 (25.91)
Stage 3: 30-59 ml/min
37 (34.3)
20 (17.9)
57 (25.91)
Stag3 4/5: <30 ml/min
13 (12.0)
2 (1.8)
15 (6.82)
modified CG (mL/min): Mean (SD)
59.68 (33.83)
75.26 (31.01)
67.61 (33.28)
0.0005
CrCl (mL/min): N(%)
0.0001
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<50 ml/min
53 (49.1)
26 (23.2)
79 (35.91)
≥50 ml/min
55 (50.9)
86 (76.8)
141 (64.09)
LMWH level: Mean (SD)
0.80 (0.33)
0.90 (0.35)
0.85 (0.34)
0.03
LMWH >1.0: N(%)
0.05
Missing
0 (0.0)
0 (0.0)
0 (0.00)
≤1.0
86 (79.6)
75 (67.0)
161 (73.18)
>1.0
22 (20.4)
37 (33.0)
59 (26.82)
LMWH
0.07
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<0.5
17 (15.7)
8 (7.1)
25 (11.36)
≥0.5
91 (84.3)
104 (92.9)
195 (88.64)
Enoxaparin dose used (mg): Mean (SD)
75.69 (34.48)
89.06 (26.58)
82.50 (31.36)
0.002
Enoxaparin dose (mg/kg): Mean (SD)
0.79 (0.29)
0.99 (0.04)
0.89 (0.23)
<0.0001
Concurrent antiplatelet or anticoagulation treatment: N(%)
0.49
Missing
0 (0.0)
0 (0.0)
0 (0.00)
No
107 (99.1)
112 (100.0)
219 (99.55)
Yes
1 (0.9)
0 (0.0)
1 (0.45)
Clinical events after anticoagulation (choice=Death): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
99 (91.7)
102 (91.1)
201 (91.36)
Checked
9 (8.3)
10 (8.9)
19 (8.64)
Clinical events after anticoagulation (choice=ACS): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
108 (100.0)
112 (100.0)
220 (100.00)
Checked
0 (0.0)
0 (0.0)
0 (0.00)
Clinical events after anticoagulation (choice=VTE): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
107 (99.1)
110 (98.2)
217 (98.64)
Checked
1 (0.9)
2 (1.8)
3 (1.36)
Clinical events after anticoagulation (choice=Ischaemic stroke in hospital): N(%)
0.24
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
106 (98.1)
112 (100.0)
218 (99.09)
Checked
2 (1.9)
0 (0.0)
2 (0.91)
Major bleeding in hospital: N(%)
0.37
Missing
1 (0.9)
1 (0.9)
2 (0.91)
Yes
7 (6.5)
4 (3.6)
11 (5.00)
No
100 (92.6)
107 (95.5)
207 (94.09)
Indication for enoxaparin(choose as many as apply) (choice=Pulmonary embolism): N(%)
0.30
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
46 (42.6)
39 (34.8)
85 (38.64)
Checked
62 (57.4)
73 (65.2)
135 (61.36)
Indication for enoxaparin(choose as many as apply) (choice=Deep vein thrombosis): N(%)
0.01
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
71 (65.7)
54 (48.2)
125 (56.82)
Checked
37 (34.3)
58 (51.8)
95 (43.18)
Indication for enoxaparin(choose as many as apply) (choice=Atrial fibrillation): N(%)
0.11
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
86 (79.6)
99 (88.4)
185 (84.09)
Checked
22 (20.4)
13 (11.6)
35 (15.91)
Indication for enoxaparin(choose as many as apply) (choice=Myocardial infarction): N(%)
0.24
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
106 (98.1)
112 (100.0)
218 (99.09)
Checked
2 (1.9)
0 (0.0)
2 (0.91)
Indication for enoxaparin(choose as many as apply) (choice=Metallic heart valve): N(%)
0.33
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
102 (94.4)
109 (97.3)
211 (95.91)
Checked
6 (5.6)
3 (2.7)
9 (4.09)
Indication for enoxaparin (Other): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Yes
108 (100.0)
111 (99.1)
219 (99.55)
Other/Unknown
0 (0.0)
1 (0.9)
1 (0.45)
Once daily dosing
Characteristic
Non-conventional (n=29)
Conventional (n=29)
Total (n=58)
P-value
Age (y)at the time of result: Mean (SD)
71.00 (12.28)
68.70 (17.34)
69.85 (14.94)
0.56
Age (y)at the time of result: N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<65 years
10 (34.5)
9 (31.0)
19 (32.76)
≥65 years
19 (65.5)
20 (69.0)
39 (67.24)
Gender: N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Male
15 (51.7)
16 (55.2)
31 (53.45)
Female
14 (48.3)
13 (44.8)
27 (46.55)
Inpatient length of stay: Median (IQ range)
12.00 (8.00-30.00)
18.00 (7.00-28.00)
13.00 (7.25-28.75)
0.86
Height (cm): Mean (SD)
169.53 (10.09)
167.86 (11.06)
168.69 (10.52)
0.55
Weight (kg)within the week prior to dose: Mean (SD)
91.95 (36.22)
79.22 (18.40)
85.59 (29.19)
0.10
BMI: Median (IQ range)
29.04 (23.44-37.35)
28.90 (23.62-31.64)
28.97 (23.49-33.11)
0.53
BMI: N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<30 kg/m2
17 (58.6)
16 (55.2)
33 (56.90)
≥30 kg/m2
12 (41.4)
13 (44.8)
25 (43.10)
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: Mean (SD)
36.22 (22.09)
22.63 (20.61)
28.88 (22.17)
0.03
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: N(%)
<0.0001
Missing
6 (20.7)
2 (6.9)
8 (13.79)
Stage 1: >=90 ml/min
0 (0.0)
0 (0.0)
0 (0.00)
Stage 2: 60-89 ml/min
3 (10.3)
3 (10.3)
6 (10.34)
Stage 3: 30-59 ml/min
12 (41.4)
1 (3.4)
13 (22.41)
Stag3 4/5: <30 ml/min
8 (27.6)
23 (79.3)
31 (53.45)
modified CG (mL/min): Mean (SD)
39.14 (25.71)
26.69 (28.62)
32.91 (27.68)
0.09
CrCl (mL/min): N(%)
0.47
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<50 ml/min
23 (79.3)
26 (89.7)
49 (84.48)
≥50 ml/min
6 (20.7)
3 (10.3)
9 (15.52)
LMWH level: Mean (SD)
0.78 (0.31)
0.82 (0.34)
0.80 (0.32)
0.60
LMWH >1.0: N(%)
0.33
Missing
0 (0.0)
0 (0.0)
0 (0.00)
≤1.0
25 (86.2)
21 (72.4)
46 (79.31)
>1.0
4 (13.8)
8 (27.6)
12 (20.69)
LMWH
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
<0.5
6 (20.7)
5 (17.2)
11 (18.97)
≥0.5
23 (79.3)
24 (82.8)
47 (81.03)
Enoxaparin dose used (mg): Mean (SD)
84.48 (24.58)
84.83 (20.64)
84.66 (22.49)
0.95
Enoxaparin dose (mg/kg): Mean (SD)
0.99 (0.31)
1.09 (0.23)
1.04 (0.28)
0.21
Concurrent antiplatelet or anticoagulation treatment: N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
No
29 (100.0)
28 (96.6)
57 (98.28)
Yes
0 (0.0)
1 (3.4)
1 (1.72)
Clinical events after anticoagulation (choice=Death): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
28 (96.6)
27 (93.1)
55 (94.83)
Checked
1 (3.4)
2 (6.9)
3 (5.17)
Clinical events after anticoagulation (choice=ACS): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
28 (96.6)
29 (100.0)
57 (98.28)
Checked
1 (3.4)
0 (0.0)
1 (1.72)
Clinical events after anticoagulation (choice=VTE): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
28 (96.6)
29 (100.0)
57 (98.28)
Checked
1 (3.4)
0 (0.0)
1 (1.72)
Clinical events after anticoagulation (choice=Ischaemic stroke in hospital): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
29 (100.0)
29 (100.0)
58 (100.00)
Checked
0 (0.0)
0 (0.0)
0 (0.00)
Major bleeding in hospital: N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Yes
1 (3.4)
1 (3.4)
2 (3.45)
No
28 (96.6)
28 (96.6)
56 (96.55)
Indication for enoxaparin(choose as many as apply) (choice=Pulmonary embolism): N(%)
0.79
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
19 (65.5)
17 (58.6)
36 (62.07)
Checked
10 (34.5)
12 (41.4)
22 (37.93)
Indication for enoxaparin(choose as many as apply) (choice=Deep vein thrombosis): N(%)
0.60
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
14 (48.3)
17 (58.6)
31 (53.45)
Checked
15 (51.7)
12 (41.4)
27 (46.55)
Indication for enoxaparin(choose as many as apply) (choice=Atrial fibrillation): N(%)
0.58
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
21 (72.4)
18 (62.1)
39 (67.24)
Checked
8 (27.6)
11 (37.9)
19 (32.76)
Indication for enoxaparin(choose as many as apply) (choice=Myocardial infarction): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
29 (100.0)
28 (96.6)
57 (98.28)
Checked
0 (0.0)
1 (3.4)
1 (1.72)
Indication for enoxaparin(choose as many as apply) (choice=Metallic heart valve): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Unchecked
28 (96.6)
27 (93.1)
55 (94.83)
Checked
1 (3.4)
2 (6.9)
3 (5.17)
Indication for enoxaparin (Other): N(%)
1.00
Missing
0 (0.0)
0 (0.0)
0 (0.00)
Yes
29 (100.0)
29 (100.0)
58 (100.00)
Other/Unknown
0 (0.0)
0 (0.0)
0 (0.00)
Once daily dosing group: N(%)
0.03
Missing
4 (13.8)
10 (34.5)
14 (24.14)
CrCl>30 once daily enoxaparin dose <1.5mg/kg
16 (55.2)
5 (17.2)
21 (36.21)
CrCl<30 once daily enoxaparin dose <1.0mg/kg
9 (31.0)
14 (48.3)
23 (39.66)
Subgroups
Anti-Xa >1.0 IU/mL
Characteristic
Non-conventional (n=26)
Conventional (n=45)
Total (n=71)
P-value
CrCl (mL/min): N(%)
0.94
<50 ml/min
12 (46.2)
19 (42.2)
31 (43.66)
≥50 ml/min
14 (53.8)
26 (57.8)
40 (56.34)
BMI: N(%)
0.12
<30 kg/m2
15 (57.7)
16 (35.6)
31 (43.66)
≥30 kg/m2
11 (42.3)
29 (64.4)
40 (56.34)
Age (y)at the time of result: N(%)
0.60
<65 years
8 (30.8)
18 (40.0)
26 (36.62)
≥65 years
18 (69.2)
27 (60.0)
45 (63.38)
Anti-Xa <0.5 IU/mL
Characteristic
Non-conventional (n=23)
Conventional (n=13)
Total (n=36)
P-value
CrCl (mL/min): N(%)
0.14
<50 ml/min
16 (69.6)
5 (38.5)
21 (58.33)
≥50 ml/min
7 (30.4)
8 (61.5)
15 (41.67)
BMI: N(%)
1.00
<30 kg/m2
15 (65.2)
8 (61.5)
23 (63.89)
≥30 kg/m2
8 (34.8)
5 (38.5)
13 (36.11)
Age (y)at the time of result: N(%)
0.69
<65 years
5 (21.7)
4 (30.8)
9 (25.00)
≥65 years
18 (78.3)
9 (69.2)
27 (75.00)
Anti-Xa (IU/mL): Median (IQR)
Non-conventional
Conventional
P-value
CrCl (mL/min): <50 ml/min
0.87 (0.66-1.14)
0.71 (0.51-0.90)
0.33
CrCl (mL/min): ≥50 ml/min
0.79 (0.62-1.02)
0.81 (0.60-0.99)
0.05
BMI: <30 kg/m2
0.76 (0.62-0.96)
0.76 (0.54-0.96)
0.005
BMI: ≥30 kg/m2
0.97 (0.73-1.16)
0.77 (0.56-0.94)
0.79
Age (y)at the time of result: <65 years
0.79 (0.64-1.02)
0.79 (0.59-0.94)
0.42
Age (y)at the time of result: ≥65 years
0.83 (0.66-1.09)
0.73 (0.52-0.95)
0.37
Model 1: All patients
Anti-Xa
Model specifications - Outcome: LMWH level - Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency - Model: Multiple linear regression     log(Anti-Xa level) ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq
Global test
model term
df1
df2
F.ratio
p.value
individualised_dose_used
1
272
7.887
0.005
age
1
272
0.065
0.8
modified_cg
1
272
0.443
0.5
bmi
1
272
4.353
0.04
enoxaparin_freq
1
272
1.487
0.2
Model summary
Var
Coefficients (95% CI)
P-value
(Intercept)
-0.528 (-0.940, -0.116)
0.01
individualised_dose_usedConventional
0.136 (0.041, 0.231)
0.005
age
0.001 (-0.004, 0.005)
0.8
modified_cg
-0.001 (-0.003, 0.001)
0.5
bmi
0.005 (0.000, 0.009)
0.04
enoxaparin_freqTwice daily
0.079 (-0.048, 0.207)
0.2
Model diagnostics
Results
Dosing strategy
Contrast
Ratio of Geometric means (95% CI)
P-value
Conventional / (Non-conventional)
1.146 (1.042, 1.261)
0.005
Adjusted means (95% CI)
individualised_dose_used
response
SE
df
lower.CL
upper.CL
Non-conventional
0.709
0.028
272
0.656
0.766
Conventional
0.812
0.031
272
0.753
0.876
Modified CrCl
Contrast
Ratio of Geometric means (95% CI)
P-value
modified_cg61 / modified_cg60
0.999 (0.997, 1.001)
0.5
BMI
Contrast
Ratio of Geometric means (95% CI)
P-value
bmi30 / bmi29
1.005 (1.000, 1.009)
0.04
Age
Contrast
Ratio of Geometric means (95% CI)
P-value
age67 / age66
1.001 (0.996, 1.005)
0.8
Dose frequency
Contrast
Ratio of Geometric means (95% CI)
P-value
Twice daily / Once daily
1.082 (0.952, 1.230)
0.2
Anti-Xa>1.0
Model specifications - Outcome: LMWH level >1.0 (yes/no) - Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency - Model: Logistic regression     Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq
Global test
LR Chisq
Df
Pr(>Chisq)
individualised_dose_used
9.484
1
0.002
age
0.476
1
0.5
modified_cg
3.641
1
0.06
bmi
3.815
1
0.05
enoxaparin_freq
2.739
1
0.10
Model summary
Var
Coefficients (95% CI)
P-value
(Intercept)
-1.672 (-4.100, 0.755)
0.2
individualised_dose_usedConventional
0.918 (0.318, 1.517)
0.003
age
-0.009 (-0.034, 0.016)
0.5
modified_cg
-0.011 (-0.023, 0.001)
0.06
bmi
0.025 (0.000, 0.050)
0.05
enoxaparin_freqTwice daily
0.687 (-0.151, 1.524)
0.1
Results
Dosing strategy
Contrast
Odds ratios (95% CI)
P-value
Conventional / (Non-conventional)
2.50 (1.37, 4.56)
0.003
Modified CrCl
Contrast
Odds ratios (95% CI)
P-value
modified_cg61 / modified_cg60
0.99 (0.98, 1.00)
0.06
BMI
Contrast
Odds ratios (95% CI)
P-value
bmi30 / bmi29
1.03 (1.00, 1.05)
0.05
Age
Contrast
Odds ratios (95% CI)
P-value
age67 / age66
0.99 (0.97, 1.02)
0.5
Dose frequency
Contrast
Odds ratios (95% CI)
P-value
Twice daily / Once daily
1.99 (0.86, 4.59)
0.1
Anti-Xa<0.5
Model specifications - Outcome: LMWH level <0.5 (yes/no) - Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency - Model: Logistic regression     Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq
Global test
LR Chisq
Df
Pr(>Chisq)
individualised_dose_used
4.859
1
0.03
age
0.058
1
0.8
modified_cg
0.006
1
0.9
bmi
5.938
1
0.01
enoxaparin_freq
1.512
1
0.2
Model summary
Var
Coefficients (95% CI)
P-value
(Intercept)
0.600 (-2.682, 3.882)
0.7
individualised_dose_usedConventional
-0.826 (-1.576, -0.076)
0.03
age
-0.004 (-0.036, 0.028)
0.8
modified_cg
0.001 (-0.014, 0.015)
0.9
bmi
-0.049 (-0.093, -0.005)
0.03
enoxaparin_freqTwice daily
-0.560 (-1.438, 0.319)
0.2
Results
Dosing strategy
Contrast
Odds ratios (95% CI)
P-value
Conventional / (Non-conventional)
0.44 (0.21, 0.93)
0.03
Modified CrCl
Contrast
Odds ratios (95% CI)
P-value
modified_cg61 / modified_cg60
1.00 (0.99, 1.01)
0.9
BMI
Contrast
Odds ratios (95% CI)
P-value
bmi30 / bmi29
0.95 (0.91, 0.99)
0.03
Age
Contrast
Odds ratios (95% CI)
P-value
age67 / age66
1.00 (0.96, 1.03)
0.8
Dose frequency
Contrast
Odds ratios (95% CI)
P-value
Twice daily / Once daily
0.57 (0.24, 1.38)
0.2
Model 1b: Twice daily dosing
Anti-Xa>1.0
Model specifications - Outcome: LMWH level >1.0 (yes/no) - Covariates: individualised dose, age, modified CrCl, BMI - Model: Logistic regression     Anti-Xa level ~ individualised dose + age + modified CrCl + BMI
Global test
LR Chisq
Df
Pr(>Chisq)
individualised_dose_used
9.349
1
0.002
age
0.073
1
0.8
modified_cg
3.815
1
0.05
bmi
5.849
1
0.02
Model summary
Var
Coefficients (95% CI)
P-value
(Intercept)
-1.498 (-4.515, 1.519)
0.3
individualised_dose_usedConventional
1.037 (0.351, 1.724)
0.003
age
-0.004 (-0.034, 0.026)
0.8
modified_cg
-0.014 (-0.028, 0.000)
0.06
bmi
0.033 (0.006, 0.060)
0.01
Results
Dosing strategy
Contrast
Odds ratios (95% CI)
P-value
Conventional / (Non-conventional)
2.82 (1.42, 5.61)
0.003
Modified CrCl
Contrast
Odds ratios (95% CI)
P-value
modified_cg61 / modified_cg60
0.99 (0.97, 1.00)
0.06
BMI
Contrast
Odds ratios (95% CI)
P-value
bmi30 / bmi29
1.03 (1.01, 1.06)
0.02
Age
Contrast
Odds ratios (95% CI)
P-value
age67 / age66
1.00 (0.97, 1.03)
0.8
Anti-Xa<0.5
Model specifications - Outcome: LMWH level <0.5 (yes/no) - Covariates: individualised dose, age, modified CrCl, BMI - Model: Logistic regression     Anti-Xa level ~ individualised dose + age + modified CrCl + BMI
Global test
LR Chisq
Df
Pr(>Chisq)
individualised_dose_used
5.999
1
0.01
age
0.059
1
0.8
modified_cg
0.290
1
0.6
bmi
5.942
1
0.01
Model summary
Var
Coefficients (95% CI)
P-value
(Intercept)
0.136 (-4.015, 4.286)
0.9
individualised_dose_usedConventional
-1.117 (-2.043, -0.191)
0.02
age
-0.005 (-0.046, 0.036)
0.8
modified_cg
0.005 (-0.013, 0.022)
0.6
bmi
-0.056 (-0.108, -0.005)
0.03
Results
Dosing strategy
Contrast
Odds ratios (95% CI)
P-value
Conventional / (Non-conventional)
0.33 (0.13, 0.83)
0.02
Modified CrCl
Contrast
Odds ratios (95% CI)
P-value
modified_cg61 / modified_cg60
1.00 (0.99, 1.02)
0.6
BMI
Contrast
Odds ratios (95% CI)
P-value
bmi30 / bmi29
0.95 (0.90, 1.00)
0.03
Age
Contrast
Odds ratios (95% CI)
P-value
age67 / age66
0.99 (0.96, 1.04)
0.8
Model 1c: Once daily dosing
Anti-Xa>2.0
Only univariate test performed due to small sample size.
Model specifications - Outcome: LMWH level >2.0 (yes/no) - Covariates: individualised dose - Analysis: Fisher’s exact test     Anti-Xa level ~ individualised dose
Non-conventional
Conventional
LMWH: ≤2.0
0
0
LMWH: >2.0
16
5
P-value (Fisher’s exact test): 1
Anti-Xa<1.0
Only univariate test performed due to small sample size.
Model specifications - Outcome: LMWH level <1.0 (yes/no) - Covariates: individualised dose - Analysis: Fisher’s exact test     Anti-Xa level ~ individualised dose
Non-conventional
Conventional
LMWH: <1.0
15
3
LMWH: ≥1.0
1
2
P-value (Fisher’s exact test): 0.1
Anti-Xa>1.0
Only univariate test performed due to small sample size.
Model specifications - Outcome: LMWH level >1.0 (yes/no) - Covariates: individualised dose - Analysis: Fisher’s exact test     Anti-Xa level ~ individualised dose
Non-conventional
Conventional
LMWH: ≤1.0
9
11
LMWH: >1.0
0
3
P-value (Fisher’s exact test): 0.3
Anti-Xa<0.5
Only univariate test performed due to small sample size.
Model specifications - Outcome: LMWH level <0.5 (yes/no) - Covariates: individualised dose - Analysis: Fisher’s exact test     Anti-Xa level ~ individualised dose
Non-conventional
Conventional
LMWH: <0.5
5
0
LMWH: ≥0.5
11
5
P-value (Fisher’s exact test): 0.3
Model 2: Conventionally dosed patients
Anti-Xa
Model specifications - Outcome: LMWH level - Covariates: age, modified CrCl, BMI, dosing frequency - Model: Multiple linear regression     log(Anti-Xa level) ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq
Model specifications - Outcome: LMWH level >1.0 (yes/no) - Covariates: age, modified CrCl, BMI, dosing frequency - Model: Logistic regression     Anti-Xa level ~ age + modified CrCl + BMI + enoxaparin_freq
Global test
LR Chisq
Df
Pr(>Chisq)
age
2.981
1
0.08
modified_cg
9.309
1
0.002
bmi
5.865
1
0.02
enoxaparin_freq
4.568
1
0.03
Model summary
Var
Coefficients (95% CI)
P-value
(Intercept)
0.035 (-3.020, 3.091)
1.0
age
-0.029 (-0.061, 0.004)
0.09
modified_cg
-0.026 (-0.044, -0.008)
0.004
bmi
0.054 (0.009, 0.100)
0.02
enoxaparin_freqTwice daily
1.312 (0.059, 2.566)
0.04
Results
Modified CrCl
Contrast
Odds ratios (95% CI)
P-value
modified_cg61 / modified_cg60
0.97 (0.96, 0.99)
0.004
BMI
Contrast
Odds ratios (95% CI)
P-value
bmi30 / bmi29
1.06 (1.01, 1.10)
0.02
Age
Contrast
Odds ratios (95% CI)
P-value
age67 / age66
0.97 (0.94, 1.00)
0.09
Dose frequency
Contrast
Odds ratios (95% CI)
P-value
Twice daily / Once daily
3.72 (1.06, 13.01)
0.04
Anti-xa<0.5
Model specifications - Outcome: lmwh level <0.5 (yes/no) - Covariates: age, modified crcl, bmi, dosing frequency - Model: Logistic regression     Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq
Global test
LR Chisq
Df
Pr(>Chisq)
age
0.176
1
0.7
modified_cg
1.482
1
0.2
bmi
1.396
1
0.2
enoxaparin_freq
3.631
1
0.06
Model summary
Var
Coefficients (95% CI)
P-value
(Intercept)
-1.393 (-6.752, 3.966)
0.6
age
0.011 (-0.042, 0.064)
0.7
modified_cg
0.015 (-0.010, 0.040)
0.2
bmi
-0.052 (-0.146, 0.043)
0.3
enoxaparin_freqTwice daily
-1.592 (-3.232, 0.049)
0.06
Results
Modified CrCl
Contrast
Odds ratios (95% CI)
P-value
modified_cg61 / modified_cg60
1.02 (0.99, 1.04)
0.2
BMI
Contrast
Odds ratios (95% CI)
P-value
bmi30 / bmi29
0.95 (0.86, 1.04)
0.3
Age
Contrast
Odds ratios (95% CI)
P-value
age67 / age66
1.01 (0.96, 1.07)
0.7
Dose frequency
Contrast
Odds ratios (95% CI)
P-value
Twice daily / Once daily
0.20 (0.04, 1.05)
0.06
Model 3: Individually dosed patients
Anti-Xa
Model specifications - Outcome: LMWH level - Covariates: age, modified CrCl, BMI, dosing frequency - Model: Multiple linear regression     log(Anti-Xa level) ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq
Global test
model term
df1
df2
F.ratio
p.value
age
1
132
0.079
0.8
modified_cg
1
132
0.468
0.5
bmi
1
132
0.885
0.3
enoxaparin_freq
1
132
0.003
1.0
Model summary
Var
Coefficients (95% CI)
P-value
(Intercept)
-0.515 (-1.141, 0.111)
0.1
age
0.001 (-0.005, 0.007)
0.8
modified_cg
0.001 (-0.002, 0.004)
0.5
bmi
0.003 (-0.003, 0.008)
0.3
enoxaparin_freqTwice daily
0.005 (-0.166, 0.176)
1.0
Model diagnostics
Results
Modified CrCl
Contrast
Ratio of Geometric means (95% CI)
P-value
modified_cg61 / modified_cg60
1.001 (0.998, 1.004)
0.5
BMI
Contrast
Ratio of Geometric means (95% CI)
P-value
bmi30 / bmi29
1.003 (0.997, 1.008)
0.3
Age
Contrast
Ratio of Geometric means (95% CI)
P-value
age67 / age66
1.001 (0.994, 1.007)
0.8
Dose frequency
Contrast
Ratio of Geometric means (95% CI)
P-value
Twice daily / Once daily
1.005 (0.846, 1.194)
1.0
Anti-xa>1.0
Model specifications - Outcome: lmwh level >1.0 (yes/no) - Covariates: age, modified crcl, bmi, dosing frequency - Model: Logistic regression     Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq
Global test
LR Chisq
Df
Pr(>Chisq)
age
0.898
1
0.3
modified_cg
0.279
1
0.6
bmi
0.974
1
0.3
enoxaparin_freq
0.407
1
0.5
Model summary
Var
Coefficients (95% CI)
P-value
(Intercept)
-3.990 (-8.124, 0.144)
0.06
age
0.020 (-0.022, 0.062)
0.3
modified_cg
0.005 (-0.013, 0.022)
0.6
bmi
0.017 (-0.016, 0.049)
0.3
enoxaparin_freqTwice daily
0.380 (-0.817, 1.578)
0.5
Results
Modified CrCl
Contrast
Odds ratios (95% CI)
P-value
modified_cg61 / modified_cg60
1.00 (0.99, 1.02)
0.6
BMI
Contrast
Odds ratios (95% CI)
P-value
bmi30 / bmi29
1.02 (0.98, 1.05)
0.3
Age
Contrast
Odds ratios (95% CI)
P-value
age67 / age66
1.02 (0.98, 1.06)
0.3
Dose frequency
Contrast
Odds ratios (95% CI)
P-value
Twice daily / Once daily
1.46 (0.44, 4.84)
0.5
Anti-xa<0.5
Model specifications - Outcome: lmwh level <0.5 (yes/no) - Covariates: age, modified crcl, bmi, dosing frequency - Model: Logistic regression     Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq